Yttrium 90-labelled edotreotide
Alternative Names: 90Y-SDZ-SMT-487; 90Y-DOTA-D-Phe1-Tyr3-octreotide; 90Y-SMT 487; OctreoTher™; Onalta; SMT-487; Y-90 SMT-487; Y-90-DOTA-tyr3-Octreotide; Yttrium 90 labelled endotreotide; Yttrium 90 labelled SMT 487Latest Information Update: 11 Dec 2015
At a glance
- Originator Novartis
- Developer Molecular Insight Pharmaceuticals; University of Iowa
- Class Antineoplastics; Cyclic peptides; Organotechnetium compounds; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuroendocrine tumours
Most Recent Events
- 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
- 06 Aug 2010 Yttrium 90-labelled edotreotide is still in phase II trials for Neuroendocrine tumours in USA
- 04 Sep 2009 Yttrium 90-labelled edotreotide sub-licensed to BioMedica Life Sciences in specific countries in Europe, the Middle East, North Africa, Russia, and Turkey